The North America neonatal jaundice management market size was valued at USD 211.43 million in 2025 and is expected to reach USD 344.70 million by 2033, at a CAGR of 6.3% during the forecast period
The market growth is largely fueled by the increasing prevalence of neonatal hyperbilirubinemia, strong healthcare infrastructure, high adoption of innovative diagnostic and phototherapy technologies and favorable reimbursement policies that support early intervention and effective care practices
Furthermore, rising emphasis on improved neonatal outcomes, expanding neonatal care facilities such as NICUs, and continuous technological progress in phototherapy and monitoring systems are enhancing the quality, accessibility, and efficiency of jaundice management in both hospital and clinical settings. These converging factors are accelerating the uptake of neonatal jaundice management solutions, thereby significantly boosting the regional industry’s growth